Milestone Pharmaceuticals Inc. announced that the FDA has set a PDUFA review goal date of March 27, 2025, for its nasal spray CARDAMYST™ (etripamil), aimed at treating Paroxysmal ...
Nasal anti-CD3 spray reduces traumatic brain injury in mice, a potential breakthrough for TBI treatment. Read now.
FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) Assuming FDA approval, proposed launch in PSVT targeted for ...
Analysts have recently evaluated Emergent BioSolutions and provided 12-month price targets. The average target is $15.0, ...
Altamira Therapeutics Ltd. (OTCQB:CYTOF) today announced that the U.S. Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for a patent (application #17/466,142) relating to the ...
Rated 4.8 out of 5 stars on Amazon, these pocket-sized strips pack a powerful, nose-clearing punch that can do wonders for ...
Influencers promoting tanning nasal sprays are popping up on the social media feeds of people around the world, especially ...
15hon MSN
In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...
A retired firefighter, Sen. Kelly Seyarto has advocated to be more involved in disaster management work. A new committee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback